

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**RESIGNATION AND APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTOR,
APPOINTMENT OF NON-EXECUTIVE DIRECTOR
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board announces that Ms. Zhang Min has tendered her resignation as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee with effect from 26 November 2018 in order to devote more time to her other work commitments. Succeeding the resignation of Ms. Zhang Min, Mr. Pan Jiuan has been appointed as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee with effect from 26 November 2018.

The Board also announces that Ms. Wang Jiafen has been appointed as a non-executive Director with effect from 26 November 2018.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces that Ms. Zhang Min (“**Ms. Zhang**”) has tendered her resignation as an independent non-executive Director, a member of the audit committee (the “**Audit Committee**”) of the Company, and a member of the nomination committee (the “**Nomination Committee**”) of the Company with effect from 26 November 2018 in order to devote more time to her other work commitments.

Ms. Zhang has confirmed that there is no disagreement between her and the Board in any respect, and she is not aware of any matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude and appreciation to Ms. Zhang for her valuable contribution to the Company during her tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that succeeding the resignation of Ms. Zhang, Mr. Pan Jiuan (“**Mr. Pan**”) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee with effect from 26 November 2018.

Set out below are the personal particulars of Mr. Pan:

Mr. Pan, aged 50, obtained his bachelor degree in law from Central South University of Technology* 中南工業大學 (now known as Central South University* 中南大學) in 1991.

He obtained his qualification as a lawyer in the People’s Republic of China in 1994. He also obtained the national manager qualification* 國家一級經理人資格 from Shanghai Jiao Tong University Center for Quality Management* 上海交通大學卓越管理中心 in 2016. He further obtained the certificate of chief human resources officer from Remin University* 中國人民大學 in 2018.

Mr. Pan has over 20 years of experience in human resources and management across various industries, including education, kitchen electrical appliances, office automated facilities, textile and garment. He is currently the chief human resources officer of Shanghai Lingjiao Enterprise Management Consulting Co. Ltd* 上海領教企業管理諮詢有限公司.

From 2010 to 2013 and 2003 to 2010, he served as the corporate group director of human resources of each of K-Boxing Men’s Wear (Shanghai) Co. Ltd.* 勁霸男裝(上海)有限公司 and Ningbo Fotile Kitchen Appliances Co. Ltd.* 寧波方太廚具有限公司, respectively. From 1994 to 2002, he was the deputy manager, manager, and senior manager of Minolta Industries (HK) Limited 美能達實業(香港)有限公司.

Pursuant to the letter of appointment made between Mr. Pan and the Company, Mr. Pan has been appointed for a term of three years commencing from 26 November 2018 and is subject to retirement by rotation and eligible for re-election pursuant to the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Mr. Pan is entitled to an annual remuneration of HK\$240,000, which has been recommended by the Remuneration Committee and approved by the Board with reference to his duties and responsibilities in the Company and the prevailing market conditions.

The Company has received a written confirmation of independence according to Rule 3.13 of the Listing Rules from Mr. Pan.

As at the date of this announcement, Mr. Pan does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”). Save as disclosed above, Mr. Pan (i) does not hold any position with the Group; (ii) does not and did not hold any directorship in any public listed companies in Hong Kong or overseas in the past three years and other major appointments and qualifications; (iii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries or any of their respective associates (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information in relation to Mr. Pan that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with Mr. Pan’s appointment as an independent non-executive Director and a member of each of the Audit Committee and the Nomination Committee.

The Board would like to express its warmest welcome to Mr. Pan for joining the Board.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that, Ms. Wang Jiafen (“**Ms. Wang**”) has been appointed as a non-executive Director with effect from 26 November 2018.

Set out below are the personal particulars of Ms. Wang:

Ms. Wang, aged 67, obtained her college degree in business management from Shanghai Television University* 上海電視大學 in 1986 (now known as Shanghai Open University* 上海開放大學). She obtained her master degree in business administration from China Europe International Business School 中歐國際工商學院 in 2004.

Ms. Wang has over 40 years of experience in corporate management across various industries, including financial, food and retail services. She is currently the chairman of Shanghai Guanji Enterprise Management Consulting Co., Ltd.* 上海觀詰企業管理諮詢公司 and a coach of Shanghai Lingjiao Enterprise Management Consulting Co. Ltd* 上海領教企業管理諮詢有限公司.

She has previously served as the vice chairman of Ping An Trust Co., Ltd.* 平安信托有限責任公司 from 2011 to 2015. From 2008 to 2011, she was a partner of Granite Global Ventures 紀源資本. From 1996 to 2008, Ms. Wang served as the chairman and general manager of Bright Dairy Co., Ltd.* 光明乳業股份有限公司 (SHA: 600597). From 1992 to 2002, she served as the chairman and general manager of Shanghai Dairy Company.* 上海市牛奶公司.

Ms. Wang has been serving as an independent director of UE Furniture Co, Ltd. 浙江永藝傢俱股份有限公司(SHA:603600) since 2017, an independent director of Zhende Medical Co., Ltd 振德醫療用品股份有限公司(SHA: 603301) since 2016, a director of Meinian Onehealth Healthcare Holdings Co., Ltd 美年大健康產業控股股份有限公司(SZ:002044) since 2013 and a director of Shanghai Xintonglian Packaging Co., Ltd 上海新通聯包裝股份有限公司 (SHA: 603022) since 2011. She has also served as an independent director of Eurocrane (China) Co., Ltd* 法蘭泰克重工股份有限公司 (SHA: 603966) from 2017 to 2018.

The Board believes that the extensive experience of Ms. Wang in corporate management will bring new impetus to the Board, and therefore further improve the corporate governance of the Group.

Pursuant to the letter of appointment made between Ms. Wang and the Company, Ms. Wang has been appointed for a term of three years commencing from 26 November 2018 and is subject to retirement by rotation and eligible for re-election pursuant to the articles of association of the Company and the Listing Rules. Ms. Wang is entitled to an annual remuneration of HK\$240,000, which has been recommended by the Remuneration Committee and approved by the Board with reference to her duties and responsibilities in the Company and the prevailing market conditions.

As at the date of this announcement, Ms. Wang does not have any interest in the shares of the Company within the meaning of Part XV of the SFO. Save as disclosed above, Ms. Wang (i) does not hold any position with the Group, (ii) does not and did not hold any directorship in any public listed companies in Hong Kong or overseas in the past three years and other major appointments and qualifications, (iii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries or any of their respective associates (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information in relation to Ms. Wang that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with Ms. Wang's appointment as a non-executive Director.

The Board would like to express its warmest welcome to Ms. Wang for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the above-mentioned changes to the Audit Committee and the Nomination Committee:

- (i) the Audit Committee would comprise all of the three independent non-executive Directors, namely Mr. Dai Zumian (as the Chairman), Mr. Guo Hongxin and Mr. Pan, as members;
- (ii) the Remuneration Committee would comprise one executive director of the Company, namely, Ms. Wang Ye, as member, and two independent non-executive Directors, namely Mr. Guo Hongxin (as the Chairman), and Mr. Dai Zumian, as member; and
- (iii) the Nomination Committee would comprise one executive director of the Company, namely Mr. Zhang Fangliang (as the Chairman), and two independent non-executive Directors, namely Mr. Dai Zumian, and Mr. Pan, as members.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 26 November 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*